Humacyte, Inc. (HUMAW) Financials

HUMAW Assets vs Liabilities
DateAssetsLiabilities
March 31, 2026 110.6 million 98.9 million
Dec. 31, 2025 116.4 million 113.3 million
Sept. 30, 2025 91.5 million 96.3 million
June 30, 2025 138.8 million 134.7 million

HUMAW Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
March 31, 2026 -25.3 million 3.2 million
Dec. 31, 2025 -26.2 million 2.5 million
Sept. 30, 2025 -24.0 million 2.5 million
June 30, 2025 -27.0 million 2.3 million

HUMAW Net Income

No data available :(

HUMAW Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
March 31, 2026 48.5 million 63.5 million 30.0 million
Dec. 31, 2025 50.5 million 35.4 million 27.0 million
Sept. 30, 2025 19.5 million - 29.8 million
June 30, 2025 38.0 million 66.7 million 15.1 million

HUMAW Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
March 31, 2026 197.8 million
Dec. 31, 2025 158.2 million
Sept. 30, 2025 158.3 million
June 30, 2025 155.4 million

HUMAW Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
March 31, 2026 175000 19.5 million 7.9 million -
Dec. 31, 2025 39000 14.6 million 5.8 million -
Sept. 30, 2025 49000 17.3 million 5.7 million -
June 30, 2025 568000 22.0 million 7.8 million -

HUMAW Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
March 31, 2026 495000 2.0 million
Dec. 31, 2025 467000 10.9 million
Sept. 30, 2025 753000 2.1 million
June 30, 2025 301000 2.1 million

HUMAW Revenue by Segment
Graph available only for paid members. Upgrade to see it.

HUMAW

Price: $0.01

52 week price:
0.01
0.23

Earnings Per Share: -3.16 USD

Exchange: NMS

Sector: Healthcare

Industry: Biotechnology

Volume: 31189

Market Capitalization: 66.2 million

Links: